ACHV trades 135.0% below Wall Street's consensus target of $15.25.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ACHV achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 24, 2026, Achieve Life Sciences, Inc. (ACHV) has a Wall Street consensus price target of $15.25, based on estimates from 6 covering analysts. With the stock currently trading at $6.49, this represents a potential upside of +135.0%. The company has a market capitalization of $666M.
Analyst price targets range from a low of $12.00 to a high of $18.00, representing a 39% spread in expectations. The median target of $15.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ACHV trades at a trailing P/E of -5.2x. Analysts expect EPS to grow -19.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PTGXProtagonist Therapeutics, Inc. | $8.9B | $138.43 | $177.25 | +28.0% | Buy | 29.5x | 26 |
 ATAIAtai Beckley Inc. | $2.7B | $7.35 | $7.69 | +4.6% | Hold | — | 8 |
 GFAIGuardforce AI Co., Limited | $4M | $0.19 | — | — | — | — | — |
 OWLTOwlet, Inc. | $74M | $4.10 | $108.00 | +2534.1% | Buy | — | 6 |
 CHRSCoherus Oncology, Inc. | $124M | $1.01 | $6.02 | +496.0% | Buy | — | 17 |
 PRAXPraxis Precision Medicines, Inc. | $7.1B | $252.96 | $611.69 | +141.8% | Buy | — | 18 |
 CLOVClover Health Investments, Corp. | $2.4B | $4.60 | $5.50 | +19.6% | Hold | 82.1x | 9 |
 MNKDMannKind Corporation | $1.0B | $3.19 | $10.00 | +213.5% | Buy | — | 21 |
 AVDLAvadel Pharmaceuticals plc | $2.1B | $21.64 | $21.43 | -1.0% | Buy | 28.3x | 14 |
 ABBVAbbVie Inc. | $504.7B | $285.64 | $294.00 | +2.9% | Buy | 20.5x | 44 |
Quick answers to the most common questions about buying ACHV stock.
The consensus Wall Street price target for ACHV is $15.25, representing 135.0% upside from the current price of $6.49. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ACHV has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $15.25 implies 135.0% upside from current levels.
ACHV's current price is $6.49 with a consensus target of $15.25 (135.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $18 for ACHV, while the most conservative target is $12. The consensus of $15.25 represents the median expectation. These targets typically reflect 12-month expectations.
ACHV is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ACHV stock forecast based on 6 Wall Street analysts shows a consensus price target of $15.25, with estimates ranging from $12 (bear case) to $18 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ACHV, with a "Buy" consensus rating and $15.25 price target (135.0% upside). 6 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ACHV analyst price targets range from $12 to $18, a 39% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $15.25 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.